Arab Board Urology Clinical Exam

Practice session

A 66-year-old male with moderate-to-severe lower urinary tract symptoms (IPSS 22), peak urinary flow rate (Qmax) 10 mL/s, and an enlarged prostate volume of 55 mL is initiated on combination medical therapy with Tamsulosin (0.4 mg daily) and Dutasteride (0.5 mg daily). What is the distinct mechanism of action and the long-term clinical outcome of adding a 5-alpha reductase inhibitor (5-ARI) compared to alpha-blocker monotherapy alone?

Loading your practice session…